Tesla Inc. (NASDAQ: TSLA) is scheduled to report first quarter 2019 earnings results on Wednesday, April 24, after the closing bell. Analysts expect the company to report a loss of $0.69 per share on revenue of $5.33 billion.
Earlier this month, Tesla provided a disappointing vehicle deliveries report which stated that its first quarter deliveries had significantly declined on a sequential basis. Although deliveries were up 110% year-over-year, the sequential drop has raised concerns.
Tesla faces tough competition in the electric car sector and the company is adding new features to its vehicles to drive sales. Amid lower deliveries and price cuts, updates on the production and deliveries targets for the Model X, Model S and Model 3 vehicles is an area to keep an eye on. Aside from these models, updates on the new Model Y is also something to look for.
It is also important to watch out for the company’s statements on its cash position, profitability guidance and automotive gross margins. The drop in deliveries and price cuts might have weighed on the margins while the bottom line could see a negative impact from charges, unfavorable pricing and higher duties on imports from China.
Tesla’s cash position is an area to watch. During the first quarter, the company paid off a $920 million bond and updates on the cash position will provide an indication of the need to raise capital going forward.
Tesla’s sales are likely to benefit from higher energy generation and storage revenue in the first quarter. Investors should also look for updates on the company’s store closures and changes in sales strategy.
During the fourth quarter, Tesla beat revenue expectations but missed on earnings. The company reported adjusted earnings of $1.93 on revenue of $7.2 billion.
Tesla’s shares have dropped 21% thus far this year and 7% over the past 12 months.
Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
